TFA Therapeutics, Inc. (RAJAF): Cost of Revenue

Annual figures by period end, from SEC filings.

$484.6K

Year ended 2025-12-31

+227.9%

3-year compound annual growth

2021-12-31 Cost of Revenue (USD) 2025-12-31

Period ended	Cost of Revenue	Change YoY	Source filing
2025-12-31	$484.6K	+39.7%	2026-05-15, From 2025-01-01
2024-12-31	$347.0K	+198.8%	2026-05-15, From 2024-01-01
2023-12-31	$116.1K	+744.9%	2026-05-15, From 2023-01-01
2022-12-31	$13.7K	-98.7%	2025-09-23, From 2022-01-01
2021-12-31	$1.06M	n/a	2023-05-15, From 2021-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Medicinal Chemicals & Botanical Products), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Cost of Revenue	Change YoY
TFA Therapeutics, Inc. (RAJAF)	2025-12-31	$484.6K	+39.7%
Adia Med, Inc. (ADIA)	2025-12-31	$508.8K	n/m
Target Group Inc. (CBDY)	2025-12-31	$1.81M	-36.7%
Healthy Extracts Inc. (HYEX)	2025-12-31	$2.09M	+73.8%
China Foods Holdings Ltd. (CFOO)	2025-12-31	$297.9K	+66.0%
Nutra Pharma Corp (NPHC)	2025-12-31	$183.7K	+116.5%
Functional Brands Inc. (MEHA)	2025-12-31	$3.13M	+5.7%
Bon Natural Life Ltd (BON)	2025-09-30	$14.79M	-11.6%
Charlie's Holdings, Inc. (CHUC)	2025-12-31	$15.26M	+212.2%

Compare RAJAF, ADIA, CBDY, HYEX side by side · Screen every company in Medicinal Chemicals & Botanical Products ↗